CLINICAL SIGNIFICANCE OF DETERMINATION OR URINARY CONCENTRATION OF ENDOTHELIAL DYSFUNCTION AND FIBROGENESIS MARKERS IN HYPERTENSIVE NEPHROPATHY


Cite item

Full Text

Abstract

Purpose. Determination of urinary excretion of molecular markers of endothelial dysfunction and fibrogenesis and evaluation of its relationship with clinical and laboratory signs of hypertensive nephropathy.
Materials and methods. The study enrolled 71 patients with essential arterial hypertension (EAH) stages I-III, according to the classification of Russian Medical Society of Arterial Hypertension, aged 18 to 67 years (mean age, 40.9 ± 14.9 years). Along with physical examination, concentration of transforming growth factor-β1 (TGF-β1) in the urine, vascular endothelial growth factor (VEGF), plasminogen activator inhibitor type 1 (PAI-1) and collagen type IV were examined in all patients.
Results. By comparison with normotensive controls, significant increase in urinary excretion of TGF-β1, VEGF and PAI-1 was observed in patients with EAH. The concentration of these neurotransmitters, as well as type IV collagen in urine was significantly higher in the presence of microalbuminuria.
Conclusion. High concentration of TGF-β 1, VEGF and PAI-1 in the urine may be considered as an early sign of hypertensive nephropathy. Increased urinary excretion of type IV collagen is associated with microalbuminuria and gives evidence in favor of activation of renal fibrogenesis

References

  1. Мухин Н.А., Моисеев В.С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестник РАМН 2003; 11: 50-55.
  2. Ochodnicky P., Henning R.H., van Dokkum R.P., de Zeeuw D. Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. Cardiovasc. Pharmacol. 2006; 47 (Suppl. 2): S151-S162.
  3. Rosario R.F., Wesson D.E. Primary hypertension and nephropathy. Curr. Opin. Nephrol. Hypertens. 2006; 15(2): 130-134.
  4. De Jong P.E., Brenner B.M. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int. 2004; 66: 2109-2118.
  5. Комитет экспертов Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). М., 2008.
  6. Бобкова И.Н., Чеботарева Н.В., Козловская Л.В. и др. Экскреция с мочой моноцитарного хемотаксического протеина-1 и трансформирующего фактора роста-β1 как показатель прогрессирования хронического гломерулонефрита // Терапевтический архив. 2006. № 5. С. 9-14.
  7. Ochodnicky P., Henning R.H., van Dokkum R.P. et al. Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. Cardiovasc. Pharmacol. 2006; 47 (Suppl. 2): S151-S162.
  8. Hamet P., Hadrava V., Kruppa U. et al. Transforming growth factor beta 1 expression and effect in aortic smooth muscle cells from spontaneously hypertensive rats. Hypertension. 1991;17 (6 Pt. 2): 896-901.
  9. Chobanian A.V., Bakris G.L., Black H.R. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC VI Report. J.A.M.A. 2003; 289: 2560-2571.
  10. Knight E.L., Kramer H.M., Curhan G.C. High-normal blood pressure and microalbuminuria. Am. J. Kidney Dis. 2003; 41: 588-595.
  11. Roson M.I., Cao G., Della Penna S. et al. Angiotensin II increases intrarenal transforming growth factor-beta1 in rats submitted to sodium overload independently of blood pressure. Hypertens. Res. 2008; 31(4): 707-715.
  12. Jing L., Zhang J.Z., Zhao L. et al. High-expression of transforming growth factor beta1 and phosphorylation of extracellular signal-regulated protein kinase in vascular smooth muscle cells from aorta and renal arterioles of spontaneous hypertension rats. Clin. Exp. Hypertens. 2007; 29(2): 107-117.
  13. Lavoie P., Robitaille G., Agharazii M. et al. Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J. Hypertens. 2005; 23(10): 1895-1903.
  14. Sharma K., Cook A., Smith M. et al. TGF-beta impairs renal autoregulation via generation of ROS. Am. J. Physiol. Renal. Physiol. 2005; 288(5): F1069-F1077.
  15. Hocevar B.A., Howe P.H. Analysis of TGF-beta-mediated synthesis of extracellular matrix components. Methods Mol. Biol. 2000; 142: 55-65.
  16. Ulfhammer E., Ridderstrale W., Andersson M. et al. Prolonged cyclic strain impairs the fibrinolytic system in cultured vascular endothelial cells. J. Hypertens. 2005; 23(8): 1551-1557.
  17. van Leeuwen R.T., Kol A., Andreotti F. et al. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation. 1994; 90(1): 362-368.
  18. Furumoto T., Fujii S., Nishihara K. et al. Maladaptive arterial remodeling with systemic hypertension associated with increased concentrations in blood of plasminogen activator inhibitor type-1 (PAI-1). Am. J. Cardiol. 2004; 93(8): 997-1001.
  19. Kiefer F.N., Neysari S., Humar R. et al. Hypertension and angiogenesis. Curr. Pharm. Des. 2003; 9(21): 1733-1744.
  20. Gu J.W., Manning R.D. Jr., Young E. et al. Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009; 297(1): R142-R148.
  21. Stumpf C., Jukic J., Yilmaz A. et al. Elevated VEGF-plasma levels in young patients with mild essential hypertension. Eur. J. Clin. Invest. 2009; 39(1): 31-36.
  22. Walter A., Etienne-Selloum N., Sarr M. et al. Angiotensin II induces the vascular expression of VEGF and MMP-2 in vivo: preventive effect of red wine polyphenols. J. Vasc. Res. 2008; 45(5): 386-394.
  23. Tsai W.C., Li Y.H., Huang Y.Y. et al. Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension. Clin. Sci. (Lond). 2005; 109(1): 39-43.
  24. Gilbert R.E., Akdeniz A., Weitz S. et al. Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. Diabetes Care. 2003; 26(9): 2632-2636.
  25. Ellis D., Forrest K.Y., Erbey J. et al. Urinary measurement of transforming growth factor-beta and type IV collagen as new markers of renal injury: application in diabetic nephropathy. Clin. Chem. 1998; 44(5): 950-956.
  26. Lee E.Y., Chung C.H., Khoury C.C. et al. The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability. Am. J. Physiol. Renal Physiol. 2009; 297(1): F85-F94.
  27. Yu Y., Suo L., Yu H. et al. Insulin resistance and endothelial dysfunction in type 2 diabetes patients with or without microalbuminuria. Diabetes Res. Clin. Pract. 2004; 65(2): 95-104.
  28. Hirano T., Kashiwazaki K., Moritomo Y. et al. Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients. Diabetes Res. Clin. Pract. 1997; 36(1): 11-18.
  29. Nicholas S.B., Aguiniga E., Ren Y. et al. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int. 2005; 67(4): 1297-1307.
  30. Huang Y., Border W.A., Yu L. et al. A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J. Am. Soc. Nephrol. 2008; 19(2): 329-338.
  31. Ayerden Ebinç F., Haksun E., Ulver D.B. et al. The relationship between vascular endothelial growth factor (VEGF) and microalbuminuria in patients with essential hypertension. Intern. Med. 2008; 47(17): 1511-1516.
  32. Watanabe H., Sanada H., Shigetomi S. et al. Urinary excretion of type IV collagen as a specific indicator of the progression of diabetic nephropathy. Nephron. 2000; 86(1): 27-35.
  33. Tomino Y., Suzuki S., Azushima C. et al. Asian multicenter trials on urinary type IV collagen in patients with diabetic nephropathy. J. Clin. Lab. Anal. 2001; 15(4): 188-192.
  34. Sato A., Tabata M., Hayashi K. et al. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy. Clin. Exp. Nephrol. 2003; 7(3): 215-220.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies